Patient characteristics
UPN . | Age, y . | Sex . | Diagnosis . | FAB . | PBB . | Karyotype . | WBC . | Hb . | Plt . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 39 | F | T-NHL | NA | 18 | 46,XX | 99.7 | 9.4 | 260 |
| 2 | 74 | F | AML | M4 | 80 | 46,XX | 117.8 | 9.9 | 277 |
| 3 | 48 | M | AML | M3 | 96 | 46,XY t(15;17) | 38.9 | 9.5 | 13 |
| 4 | 56 | M | AML | M1 | 95 | 46,XY | 17.4 | 7.4 | 18 |
| 5 | 63 | M | AML | M4 | 58 | 46,XY; t(9;22;5) | 87.3 | 9.0 | 28 |
| 6 | 43 | M | AML | M4 | 99 | 46,XY | 72.0 | 13.7 | 32 |
| 7 | 43 | F | AML | M1 | 92 | 47,XX;+8 | 9.0 | 9.0 | 86 |
| 8 | 69 | F | AML | M3 | 43 | 46,XX t(15;17) | 0.9 | 8.1 | 55 |
| 9 | 69 | M | AML | M3 | 38 | 46,XY t(15;17) | 0.7 | 6.6 | 9 |
| 10 | 75 | F | AML | M2 | 66 | 46,XX | 94.0 | 11.1 | 64 |
| 11 | 25 | M | AML | M4 | 5 | 46,XY | 15.8 | 8.6 | 58 |
| 12 | 75 | F | sAML | ND | 42 | 46,XX,5q-7q- | 19.6 | 10.7 | 20 |
| 13 | 60 | F | sAML | M2 | 42 | 46,XX | 34.0 | 8.1 | 75 |
| 14 | 67 | M | sAML | M2 | 12 | 46,XY | 13.1 | 8.4 | 221 |
| 15 | 77 | F | sAML | ND | 4 | 46,XX | 64.6 | 10.0 | 111 |
| 16 | 76 | M | sAML | M4 | 34 | 46,XY | 12.9 | 12.6 | 81 |
| 17 | 60 | F | CMML | NA | 22 | 46,XX | 126.0 | 8.5 | 74 |
| 18 | 27 | F | ALL | NA | 90 | 46,XX | 12.2 | 7.7 | 41 |
| 19 | 73 | F | ALL | NA | 41 | 46,XX | 10.7 | 10.7 | 124 |
| 20 | 30 | M | CML | NA | 57* | 46,XY,t(9;22)(q34;11) | 48.0 | 15.0 | 189 |
| 21 | 41 | F | CML | NA | 47* | 46,XX,der(22)t(9;22)(q34;q11) | 183.1 | 10.5 | 812 |
| 22 | 32 | M | CML | NA | 13* | 46,XY,t(9;22)(q34;11) | 125.3 | 11.6 | 122 |
| 23 | 43 | F | CML | NA | 22* | 46,XX t(9;22) | 11.0 | 10.9 | 31 |
| 24 | 60 | M | CLL | NA | 52 | 46,XY | 20.0 | 14.7 | 775 |
| 25 | 53 | F | CLL | NA | 87 | ND | 126.1 | 13.7 | 142 |
UPN . | Age, y . | Sex . | Diagnosis . | FAB . | PBB . | Karyotype . | WBC . | Hb . | Plt . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 39 | F | T-NHL | NA | 18 | 46,XX | 99.7 | 9.4 | 260 |
| 2 | 74 | F | AML | M4 | 80 | 46,XX | 117.8 | 9.9 | 277 |
| 3 | 48 | M | AML | M3 | 96 | 46,XY t(15;17) | 38.9 | 9.5 | 13 |
| 4 | 56 | M | AML | M1 | 95 | 46,XY | 17.4 | 7.4 | 18 |
| 5 | 63 | M | AML | M4 | 58 | 46,XY; t(9;22;5) | 87.3 | 9.0 | 28 |
| 6 | 43 | M | AML | M4 | 99 | 46,XY | 72.0 | 13.7 | 32 |
| 7 | 43 | F | AML | M1 | 92 | 47,XX;+8 | 9.0 | 9.0 | 86 |
| 8 | 69 | F | AML | M3 | 43 | 46,XX t(15;17) | 0.9 | 8.1 | 55 |
| 9 | 69 | M | AML | M3 | 38 | 46,XY t(15;17) | 0.7 | 6.6 | 9 |
| 10 | 75 | F | AML | M2 | 66 | 46,XX | 94.0 | 11.1 | 64 |
| 11 | 25 | M | AML | M4 | 5 | 46,XY | 15.8 | 8.6 | 58 |
| 12 | 75 | F | sAML | ND | 42 | 46,XX,5q-7q- | 19.6 | 10.7 | 20 |
| 13 | 60 | F | sAML | M2 | 42 | 46,XX | 34.0 | 8.1 | 75 |
| 14 | 67 | M | sAML | M2 | 12 | 46,XY | 13.1 | 8.4 | 221 |
| 15 | 77 | F | sAML | ND | 4 | 46,XX | 64.6 | 10.0 | 111 |
| 16 | 76 | M | sAML | M4 | 34 | 46,XY | 12.9 | 12.6 | 81 |
| 17 | 60 | F | CMML | NA | 22 | 46,XX | 126.0 | 8.5 | 74 |
| 18 | 27 | F | ALL | NA | 90 | 46,XX | 12.2 | 7.7 | 41 |
| 19 | 73 | F | ALL | NA | 41 | 46,XX | 10.7 | 10.7 | 124 |
| 20 | 30 | M | CML | NA | 57* | 46,XY,t(9;22)(q34;11) | 48.0 | 15.0 | 189 |
| 21 | 41 | F | CML | NA | 47* | 46,XX,der(22)t(9;22)(q34;q11) | 183.1 | 10.5 | 812 |
| 22 | 32 | M | CML | NA | 13* | 46,XY,t(9;22)(q34;11) | 125.3 | 11.6 | 122 |
| 23 | 43 | F | CML | NA | 22* | 46,XX t(9;22) | 11.0 | 10.9 | 31 |
| 24 | 60 | M | CLL | NA | 52 | 46,XY | 20.0 | 14.7 | 775 |
| 25 | 53 | F | CLL | NA | 87 | ND | 126.1 | 13.7 | 142 |
UPN indicates uniform patient number; FAB, French-American-British classification; PBB, peripheral blood blasts given in percent of nucleated cells; WBC, white blood count in Giga/L; Hb, hemoglobin in g/dL; Plt, platelets in Giga/L; F, female; M, male; NA, not applicable; and ND, not determined.
Percent immature myeloid cells.